to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
Low-dose smoking resumption in ex-smokers with refractory ulcerative colitis.
Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Vedolizumab as induction and maintenance therapy for Crohn's disease.
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial.
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.